Autobahn Therapeutics

Autobahn Therapeutics is a biotechnology company based in San Diego, California, with a team of 30 employees. The company is dedicated to improving the lives of individuals impacted by central nervous system (CNS) disorders. Autobahn Therapeutics focuses on developing therapies that promote the body's natural regenerative capabilities to address these conditions. Their primary area of research involves thyroid hormone receptor beta agonists, which they believe hold significant potential for treating CNS disorders. Their lead candidate, ABX-002, is being investigated for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. The company distinguishes itself through its deep understanding of human biology and its development of a specialized brain-targeting chemistry platform. This platform enables them to develop targeted therapies that aim to modify the root cause of CNS diseases, potentially offering a more effective approach than existing treatments. For more information about Autobahn Therapeutics and their groundbreaking research, please visit their website at autobahntx.com.